This clinical trial is focused on studying the effects of two medical conditions, heart disease and hypoalbuminemia, which is a condition where there is a low level of albumin in the blood. The study will explore how these conditions affect the way the body processes a medication called cefazolin, which is commonly used to prevent infections during surgery. Additionally, the study will involve the use of Human Albumin, a protein solution given through an infusion, to see how it influences the levels of cefazolin in the body.
The purpose of the study is to understand how different levels of albumin in the blood can change the way cefazolin works in patients undergoing heart surgery. Participants will be randomly assigned to different groups, where some will receive the albumin infusion and others will not. This will help researchers compare the effects of albumin on cefazolin levels in the body. The study will be conducted in an open-label manner, meaning both the participants and the researchers will know which treatment is being administered.
Throughout the study, participants will receive the treatments intravenously, which means the medication will be delivered directly into the bloodstream through a vein. The study will monitor the concentration of cefazolin in the blood over a period of time to gather data on how the drug is processed in the body. This information will help improve understanding of how to best use cefazolin in patients with heart disease and low albumin levels, potentially leading to better treatment outcomes in the future.



Austria